Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC - Regeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga

Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC

REGNRegeneron Pharmaceuticals Inc

Edge Rankings

Momentum13.25

Growth-

Quality16.28

Value61.20

Price Trend

Short

Medium

Long

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Benzinga.com on devices